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Abstract: In urine drug testing for pain management, dilute and shoot is a common 
method used to analyze drugs in urine. Beta-glucuronidases are enzymes that are used to 
cleave glucuronide conjugates off the drug metabolite, converting it back into the parent 
drug, allowing detection of the free drug. There are several different sources of beta-
glucuronidases on the market today, including abalone, red abalone, limpet, and 
recombinant organisms. This research takes these different sources of beta-glucuronidase 
enzymes from different companies and determines the enzyme that have better hydrolysis 
efficiency. Hydrolysis efficiency is the conversion of total drug to the free drug by 
cleaving off the glucuronide portion of the drug. Six different sources were used along 
with six different drug-glucuronide conjugates, including opioids, benzodiazepines, and 
cannabinoids. Specimens were prepared using dilute and shoot methods, and guidelines 
were established to ascertain the most efficient and affordable. The guidelines stated that 
there could not be less than 40% conversion of the glucuronide conjugates to the target 
drug, it must work well across multiple drug classes and be cost efficient for a laboratory. 
Once the results were analyzed using these guidelines, a recombinant enzyme was 
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Drug testing is a significant part of most clinical laboratories.  Accurate drug 
testing allows laboratories to test for and show precise concentrations of parent drugs that 
may be in an individual’s system. Since some drugs may be present as metabolites that 
are conjugated to sugars known as glucuronides, beta-glucuronidase enzymes are 
frequently utilized for accurate drug testing. The enzyme assists in determining how 
much of a parent drug is present in an individual’s system by converting the metabolite 
back to the parent compound. There are various sources of beta-glucuronidase enzymes, 
including patella vulgata, red abalone, abalone and recombinant enzyme systems.5, 11, 14 
Research across different drug classes such as benzodiazepines, cannabinoids, and 
opioids are currently underway to determine which type of beta-glucuronidase enzyme is 
most efficient at converting drugs to their free or parent forms for analytical purposes. 
Once a drug is converted to its parent form, it can then be detected by scientific 
instrumentation. For the instrumentation in this study, the drugs need to be unconjugated 
from the glucuronide portion to allow detection of the target drug rather than the 
glucuronide metabolite. This research is an attempt to demonstrate the most efficient and 
affordable beta-glucuronidase enzyme for conversion of metabolite to parent drugs, in 
2 
 
order to further assist clinical laboratories in obtaining accurate concentration levels of 
drugs in an individual specimen.  
In order for accurate detection via liquid chromatography tandem mass 
spectrometry multiple reaction monitoring, the target drugs need to be in their free or 
parent form. Laboratories depend on the ability of the instrument to detect the drugs 
accurately, so they can report the result with confidence. This research is significant 
because it may enhance sensitivity to certain drugs if an enzyme hydrolyzes them more 
efficiently. This research also considers the financial costs of enzymes by looking at how 
many samples can be analyzed using one bottle of the company’s enzyme, as well as the 
personnel time it takes to convert a drug from its conjugated to its free form. Does the 
cost of the bottle and amount of samples that can be run using just that one bottle fit into 
a laboratory’s budget? Additionally, this research looks at how the enzyme works across 
multiple drug classes with multiple drugs in each class, whereas most research on this 
topic focuses on one individual class at a time.  
Multiple companies have manufactured beta-glucuronidase enzymes and tested 
them against those of competitors. Some companies provided optimal parameters such as 
incubation time, pH and volume of buffers, incubation temperature, and amount of beta-
glucuronidase enzyme required. Other companies’ optimal conditions were determined 
based on other research done using the enzyme or graphs from the manufacturer’s 
website. The individual studies that these companies have produced, documenting the 
validity of their enzyme to produce the optimum results, are highlighted in the literature 
review, which also goes into detail on the glucuronidation process of a drug when it 
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enters the body. In this research, beta-glucuronidase enzymes from different sources 
(recombinant, limpet, etc.) and six different companies were evaluated.  
This research was executed by using a common sample preparation method found 
in drug-testing laboratories, known as the dilute and shoot method. The factors of the 
dilute and shoot method related to enzyme are the incubation time, pH of buffer, 
incubation temperature, and the amount of enzyme that is added to each sample. This 
research will be beneficial to other laboratories by providing information on which beta-
glucuronidase enzyme converts drugs to their free form in the most efficient and cost-
effective manner.  
The aim of this paper is to determine which of the beta-glucuronidase enzymes 
performs best. In order to make this determination, the beta-glucuronidase enzyme 
performance was assessed by a set of developed guidelines. The enzyme must have a 
hydrolysis efficiency greater than 40%, which is defined as the percentage of the drug 
that is converted from its conjugated to its free form in the study. The enzyme must 
also perform well across different drug classes to be considered efficient. If the 
enzyme performs well in one or two drugs classes, but poorly in others, it was not 
considered efficient. Finally, laboratories will expect the enzyme to be cost-efficient. 
The purpose of this study is to find a beta-glucuronidase enzyme that will perform well 
in overall hydrolysis efficiency across multiple classes of drugs that is also affordable 







 Generally, drug testing is performed in clinical and forensic laboratories to 
determine the concentration levels of any legal or illegal drugs within a person’s system. 
The first step in a drug test is to collect a specimen, which is typically a blood or urine 
sample but more commonly urine since it has a wider detection window than blood.  
Currently, the dilute and shoot method is utilized by most testing laboratories for urine 
specimen analysis. In dilute and shoot, a hydrolysis solution, which includes a beta-
glucuronidase enzyme, buffer, and internal standard, is added to the sample and 
incubated at a specific temperature and for a specific amount of time. Afterwards, the 
sample is diluted down with sample diluent to reduce interference. The sample is then 
centrifuged and the supernatant is transferred to an amber vial for analysis on the 
instrument. The part of the dilute and shoot process that is critical to current research is 
the hydrolysis solution. In the hydrolysis solution, there are three components: the beta-
glucuronidase enzyme, internal standard, and acetate buffer. Of those three components, 
this research will focus on the beta-glucuronidase enzyme. 
 When a drug, such as morphine, is taken by an individual, it enters the body in the 
parent, non-metabolized, form. However, upon absorption, the body metabolizes 
morphine and conjugates it to a glucuronide to form a compound called morphine-3-
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glucuronide. In order to remove the glucuronide portion, a process called enzymatic 
hydrolysis typically using a beta-glucuronidase enzyme must occur. The beta-
glucuronidase enzyme removes the glucuronide from the drug metabolite and converts it 
back to the parent drug. The process of glucuronidation increases the drug’s water 
solubility, so the drug will be able to be effectively excreted from the body in the urine.1  
The current research looked at six different glucuronidase enzymes from six 
different companies to determine which one efficiently cleaved off the most glucuronide 
tails across different drug classes including benzodiazepines, cannabinoids, and opiates. 
This study will identify which beta-glucuronidase enzyme cleaves off the most 
glucuronide portions more efficiently, which will allow for maximum drug recovery and 
detection in the urine sample.  
Pharmacokinetics (ADME) 
When a drug is taken, it must be absorbed, distributed, metabolized and excreted 
from the body. This process is captured in the acronym ADME which stands for absorption, 
distribution, metabolism, and excretion, respectively. Taken as a whole, this is referred to 
as pharmcokinetics, and describes what the body does to the drug. The effects of the drug 
on the body are part of pharmcodynamics, but that is less critical for this particular research.   
Absorption 
Absorption is the process by which drugs enter the bloodstream in order to be 
distributed to tissues where it might have an effect. There are multiple ways in which a 
drug can enter the system: oral, inhalation, intravenous, intramuscular, rectal, oral mucosa, 
intrathecal, dermal, ocular, or intranasal. The most common route of absorption is oral. 
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When absorbed orally, the drug goes through the gastrointestinal tract. There are some 
drugs that when they are absorbed from the gastrointestinal tract they immediately go to 
the liver through the hepatic portal vein. The drug will be metabolized by enzymes inside 
the liver to an extent that most of the active ingredient in the drug will not exit the liver and 
so therefore will not enter the systemic circulation. When a drug does not enter the systemic 
circulation, it leads to a decrease in the metabolism of the drug that can result in a 
substantial increase in peak plasma concentration and systemic availability. When a drug 
is absorbed by the gastrointestinal tract, one route it can take is to enter the portal 
circulation where it goes to the liver and then travels back to the gastrointestinal tract. This 
is called enterohepatic circulation. When a drug goes through enterohepatic circulation, the 
pharmacological effects of the drug and its metabolites are drawn out. If an individual 
wants the entire amount of drug to be absorbed, then the individual would absorb the drug 
intravenously. By absorbing a drug intravenously, the individual is getting the entire drug 
in their system and getting the drug into the bloodstream faster. With the other routes of 
absorption, only a variable amount of the drug is getting into the system. The 
bioavailability, which is the amount of drug absorbed relative to the amount that is 
administered, can be affected by different properties. Those properties include solubility, 
concentration, surface area, blood supply, and pH. Each one of these properties places a 
role in how much of the drug that is administered actually gets absorbed into the body. The 
solubility of a drug plays an important role because it the drug is in a tablet form; it must 
be broken down first before being taken into the bloodstream. If a drug tablet is coated or 
sustained release, then the drug will absorb more slowly than other forms of tablets. Drugs 
that are in an aqueous medium such as immediate release tablets, will absorb more rapidly. 
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The more concentrated a drug is, the faster it will absorb. The small intestine and the 
stomach both have large surface areas which help the process of absorption. Increased 
blood supply also helps the process the of absorption. By increasing the blood flow, the 
absorption rate of the drug will increase as well. Finally, pH will affect the absorption rate. 
In order for the drug to enter the bloodstream, it must pass through membranes. Depending 
on whether or not the drug is acidic or basic will determine how much of the drug will stay 
ionized or unionized in either the stomach or small intestine. If a drug becomes more 
ionized, then the amount of drug that is absorbed will be less than that of a unionized drug. 
In order to determine how much of a drug will be non-ionized, the Henderson-Hasselbach 
equation is used.26 
Distribution 
Distribution is the transfer of the drugs from one part of the body to another. The 
highly perfused tissues such as heart, liver, kidney, and brain will get most of the absorbed 
drug. Tissues such as muscles and fats take more time to reach equilibrium with the blood 
so those tissues don’t get as much of the absorbed drug which makes those tissues less-
perfused. Factors that affect the absorption of the drug also affect the distribution. Drugs 
that are more lipid soluble will cross the membranes more easily, which means more drug 
present in the blood which means more drug will be distributed throughout the body. The 
pH also has an effect on the distribution because it is the unionized part of the drug that is 
able to move across the membrane and be distributed into the blood stream. Plasma protein 
binding plays a role in distribution in that only unbound or free drugs can leave the blood 
and be distributed into the tissues. Those drugs that are bound to proteins will stay in the 
blood longer because of their size. Therefore, the drugs that are bound to proteins won’t be 
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able to reach their intended site and produce the effects that was intended. If multiple highly 
bound protein drugs are taken, an interaction can occur that could lead to an increased 
pharmacologic activity or toxicity. One important concept that has come from distribution 
is the volume of distribution. The volume of distribution is the amount of fluid that a drug 
dose would have been distributed if the total dose had remained in the blood.26 
Metabolism 
Metabolism is the process in which the drug is modified for elimination from the 
body. This process occurs with the help of enzymes or catalysts. Metabolism usually occurs 
in the liver. There are two different parts of metabolism: Phase I and Phase II. Phase I 
metabolism includes the reactions that convert a parent drug to a more polar drug by 
inserting a polar functional group. Some examples of Phase I reactions are reduction, N-
dealklyation, ester hydrolysis, and aromatic hydroxylation. Phase I reactions form more 
polar metabolites that can be either pharmacologically active or inactive. Then, in Phase II 
reactions, the drug or metabolite from Phase I is chemically changed into a compound that 
is soluble enough to be excreted out of the body.26 Phase II metabolism conjugates a drug 
which produces a drug that has a higher polarity, greater water solubility, and easier to 
eliminate from the body. Most Phase II metabolism reactions are catalyzed by transferase 
enzymes. The Phase II metabolism reaction product that is formed is usually the inactive 
metabolite, compared to Phase I where the active metabolite is formed. There are four 
major conjugation reactions in Phase II metabolism: methylation, sulphation, acetylation 
and glucuronidation. The majority of Phase II reactions occur in the smooth endoplasmic 
reticulum of liver cells. Liver is the main site of metabolism because that is where the 
highest concentration of metabolizing enzymes is located.27 Phase I metabolism is usually 
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followed by Phase II metabolism, although the structure of the drug determines whether or 
not a drug will undergo Phase I metabolism or not.26 A drug does not have to go through a 
Phase I metabolism reaction to be able to go through a Phase II metabolism reaction.  
An important concept with metabolism that was mentioned in the previous section 
of absorption is the first pass effect or first pass metabolism. In the first pass effect, when 
a drug is administered orally and is absorbed by the gastrointestinal tract, the drug will be 
transported through the portal vein straight to the liver, where it is metabolized. When a 
drug undergoes first pass metabolism, a small portion of the active drug will reach the 
systemic circulation in order for it to reach its target tissue. For drugs that have a high first 
pass effect, users will not take a drug orally instead they will administer the drug through 
other routes such as intravenously, sublingually, or buccally so the user can get the desired 
effect of the drug.28 
Glucuronidation  
 Glucuronidation is a vital part of drug metabolism. Glucuronidation is a type of 
conjugation reaction. Conjugation reactions with hydrophilic compounds result in a large 
increase of xenobiotic hydrophilicity, enabling the xenobiotic to be efficiently excreted 
from the body. Even though most xenobiotic compounds are highly water soluble, they are 
unable to be diffused across the plasma membrane. Therefore, the transport of the 
xenobiotic compounds involves the transport across the canalicular membrane into bile or 
across the sinusoidal membrane into blood. The reason for the xenobiotic compound to be 
unable to readily pass through the plasma membrane is because the metabolites formed by 
conjugation reactions, such as glucuronides, have lower log P and a much greater total 
polar surface area (TPSA) than their parent drug. Because of these parameters, the 
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metabolite is unable to diffuse passively across biological membranes. The drug conjugates 
are actively transported into the blood by MRP1 and MRP3 is used to transport on the 
sinusoidal membrane.2 
For mammalian species except the cat family, glucuronidation is a major pathway 
for transforming a xenobiotic so that it can be excreted from the system.2  Glucuronidation 
is considered to be a phase II reaction; however, glucuronidation is considered to be the 
initial biotransformation step in the metabolism of many drugs.3 The primary helper in 
glucuronidation is the co-factor UDP-glucuronic acid (UDPGA). UDP-glucuose, UDP-
xylose, and UDP-galactose can also be used; but for this research, UDP-glucuronic acid is 
the one that will be used the most with the drugs that are being researched. The enzyme 
that is used to catalyzed the reaction is UDP-glucuronosyltransferases (UGTs).2 UGTs are 
membrane-bound enzymes that transfer the glucuronic acid from the UDPGA to a 
nucleophilic functional group such as phenols, carboxylic acid, amines, sulfhydryl groups, 
and nucleophilic carbons. The addition of this glucuronic acid to certain molecules 
increases the polarity and the water solubility. By adding the glucuronic acid, it increases 
the ability to be excreted into bile, urine, or both.4 The UGTs catalyze the reaction which 
takes place predominantly in the endoplasmic reticulum of the liver and other tissues such 
as the kidney, GI tract, lungs, and other organs.2 
The site on the xenobiotic where the glucuronidation occurs is usually an electron-
rich O, N, or S heteroatom. The glucuronidation reactions that involve UGTs are SN2 
substitution reactions. In those substitution reactions, the nucleophilic heteroatom of the 
substrate attacks the C1 atom of the UDPGA, which results in a xenobiotic glucuronide in 
the β-configuration. The substrates used for glucuronidation are those that are small 
11 
 
lipophilic compounds that contain certain functional groups which form different 
glucuronides. Aliphatic alcohols and phenols form the O-glucuronide acetals. Acyl 
glucuronides are formed from carboxylic acids. N-glucuronides are formed from aromatic 
and aliphatic amines. Free sulfhydryl groups form the S-glucuronides. With N-
glucuronidation, there are substrates with tertiary amines that when they undergo N-
glucuronidation reaction, they will form positively charged quaternary glucuronides. Some 
of these positively charged quaternary glucuronides can be carcinogenic.2  
The co-factor for this reaction, UDPGA, is synthesized from glucose-1-phosphate. 
The linkage between the glucuronic acid and UDP is an α-configuration. This particular 
configuration protects the co-factor from hydrolysis by β-glucuronidase. One problem with 
that is the glucuronides of drugs have a β-configuration. The inversion of this configuration 
occurs because glucuronides are formed by nucleophilic attack by an electron-rich atom on 
UDPGA. The nucleophilic attack occurs on the opposite side of the linkage between 
glucuronic acid and UDP, which as mentioned above, is an α-configuration.  
Drugs that are conjugated with glucuronides are substrates for β-glucuronidase. The 
β-glucuronidase activity is mainly present in the intestinal microflora. They can also be 
present in the lysosomes of some mammalian tissues. The intestinal enzyme can release 
the aglycone, which can be reabsorbed and then enter a cycle called enterohepatic 
circulation. The aglycone is the parent compound or its unconjugated metabolites. Once 
the aglycone enters the enterohepatic circulation, it can delay the elimination of the drugs. 
N-glucuronides are generally hydrolyzed by β-glucuronidase rather slowly. Some N-
glucuronides are resistant to hydrolysis by β-glucuronidase. Some N-glucuronides are 
hydrolyzed in acidic conditions (i.e. urine), which can give the impression that the parent 
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compound was eliminated unchanged. Determining whether the glucuronide will be 
excreted via the bile or the urine depends on the size of the aglycone. In a study done on 
rats, if the molecular weight of the aglycone was less than 250, it was excreted in the urine. 
Aglycones that were higher than 350 were excreted in the bile.2  
The carboxylic acid part of the glucuronic acid promotes the excretion of the 
xenobiotic because it increases the aqueous solubility and TPSA of the xenobiotic as well 
as it is recognized by the biliary and renal organic anion transport systems. When it is 
recognized by these systems, it allows the glucuronide to be excreted into urine and bile.2  
Excretion 
Excretion is the process of removing the drug from the body. The two main routes 
in which the drug is excreted from the body is through the kidney (renal) or the liver 
(hepatic). The liver is the major site of drug metabolism. Once the drug is cleared from the 
liver, it is stored in bile from the liver that is stored in the gall bladder. From there it enters 
the small intestines where the drug is then eliminated in the feces. There are a couple of 
factors that affect the clearance of the drug from the blood to the liver. One factor is the 
blood flow to the liver. Certain diseases can either decrease or increase the blood flow to 
the liver. Another factor is the ability of the liver to remove the drug from the blood. Renal 
excretion is a function of filtration, secretion, and reabsorption. Urine is a major excretory 
pathway for drugs. Urine drug testing is what most clinical laboratories use to test for 
certain drugs. The drug can also be excreted through the breath. One good example of a 




Sources of Enzymes 
 There are different sources of beta-glucuronidases that are used in laboratories. 
Some of the different sources include abalone, red abalone, limpet, and recombinant 
organisms. While there may be other sources available, these particular sources are the 
ones that were used in this research project. 
 Abalone is part of the phylum Mollusca. The Mollusca group includes the clams, 
scallops, sea slugs, octopuses and squid. The abalone has a soft body that is surrounded by 
a mantle, anterior head and a large muscular foot.19 Most abalone have been harvested in 
Southern California. In the late 1800s, Asians began harvesting abalone intertidally which 
was in between successive tides. Then in the early 1900s, they began harvesting the abalone 
by diving. As a result of this kind of harvesting, the abalone population began to decline 
very quickly. Fast forward 50-60 years, with the developments of scuba diving, scuba 
divers could now dive more than 100 feet. These developments led to the thousands of 
abalone being taken from the ocean. In 1996, almost less than 10% of what was usually 
caught by scuba divers could actually be harvested by commercial abalone divers. Not only 
was the catching of abalone leading to the decrease, but also the environment. Several El 
Ninos that came in the 1908s and 1990s brought warmer water which lead to the decreased 
nutrient levels and decreased the kelp levels which is a main food source for abalone. Due 
to the decreased population of the abalone, the California State Department of Fish and 
Game banned the taking of abalone by either sport or commercial diving due to the fear 
that the species would become extinct. In 1970, Dr. Daniel Morse began to research how 
to spawn abalone. He found that he could “fool” the abalone into sensing hydrogen 
peroxide in the water and mistaking it for their own. The abalone would in turn release a 
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hormone and the abalone would spawn. This research led to the increase in mariculture 
farms that would spawn abalone in the 1970s. It wasn’t until the 1980s that the farms 
actually started producing the abalone. Most of the farms are private enterprises. Few of 
the farms provide maricultured abalone to restaurants in Southern California.20  
 Red abalone is one of the largest species of abalone in the world. They are well-
suited for farming both in land-and-ocean based operations. Most of the red abalone live 
in the intertidal and sub-tidal zone.21 Red abalone belongs to the same phylum as abalone 
Mollusca. They are most commonly found in Northern California. They are slow-growing 
herbivores who feed off of drift kelp. Like abalone, the red abalone population has 
decreased due to overharvesting, predation by sea otters, and disease. Fishing for abalone 
peaked in the 1950s and 60s which lead to a decline in the populations. Because of this, 
the ban of commercial fishing was done in 1997. As of today, red abalone is legally 
harvested on a restricted basis only in Northern California. Abalone Recovery and 
Management Plan was formed in 2005 by the Fish and Game Commission to regulate the 
recreational fishery in Northern California. It was also set up to aid in the recovery of the 
depleted abalone in the rest of California. As with abalone, red abalone farming has become 
a popular way of harvesting the red abalone.22  
 Limpet is an herbivorous marine snail that lives along the coast of Western Europe. 
Limpets can be found in the intertidal zone which makes them well-adapted to an 
amphibious life. Limpets are part of the same phylum as the abalones, the Mollusca. They 
have a thick, conical shell and strong muscular foot. With these type of structure, it gives 
the limpet a defense against predators in and out of the water.23 Limpets feed on the algae 
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which is found on the rock on which they live. Limpet farming is not as common as with 
the abalone.  
 Recombinant is another source of enzyme but recombinant is different from the 
other three sources already mentioned. Recombinant is primarily made in the laboratory 
by using a transformation process. With the transformation process, a piece of DNA is 
inserted into a vector, then that particular piece of DNA is cut with a restriction enzyme. 
Using DNA ligase, the DNA insert is ligated into the vector. The vector is inserted into a 
host cell where the host cell produces the enzyme. In this case, the host organism would be 
E. Coli. Different vectors have different properties to make them suitable to different 
applications, but this is the mechanism of recombinant glucuronidase production that 
produced the enzyme used in this research.29  
Drug Classes 
 Three different drugs classes were used throughout this research: benzodiazepines, 
opioids and cannabinoids. Benzodiazepines are used mainly for anxiety and other 
conditions. Benzodiazepines work in the brain by binding to a receptor and affecting the 
neurotransmitter releasing nerves that communicate with other nerves in the body. One of 
the neurotransmitters that are affected is the gamma-aminobutyric acid (GABA), which is 
an inhibitory neurotransmitter that suppresses the activity of nerves. Some examples of 
benzodiazepines include oxazepam, lorazepam, temazepam, alprazolam, diazepam, and 
flurazepam. Benzodiazepines are a Schedule IV drug which means they have a low 
potential of abuse and low risk of dependence.  
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 Opioids are a drug class that has gained a lot of attention over the years and are 
used as analgesics, or pain relievers. It is a drug class that is mainly used in pain 
management, as they act on the opioid receptors to produce morphine-like effects. Some 
examples of opioids include fentanyl, hydrocodone, oxycodone, morphine, codeine, and 
buprenorphine. Most of the opioids are under the Schedule II drug class which are drugs 
that have a high potential for abuse, with use potentially leading to severe psychological or 
physical dependence such as hydrocodone and oxycodone. There are some opioids that are 
in the Schedule III class which has a moderate to low potential for physical and 
psychological dependence, such as buprenorphine.  
 Cannabinoids are chemical compounds that act on the cannabinoid receptors in the 
body to alter the release of neurotransmitters in the brain. Cannabinoids are any various 
chemical constituent of cannabis or marijuana. As of today, cannabinoids are currently a 
Schedule I drug which means that there are no currently accepted medical use and there is 
a high potential for abuse. However, some people do self-treat themselves with this drug. 
Currently, there are four states (Colorado, Washington, Oregon and Alaska) plus District 
of Columbia that have passed laws for legalized cannabis for recreational use. Twenty-
three states plus District of Columbia have passed laws that cannabis can be used for 
medicinal purposes.30 
Drug Testing Method 
 In most urine drug testing laboratories, dilute and shoot is the method which is 
most commonly used. In dilute and shoot, a technician is diluting the drugs in the urine 
sample and then “shooting” it onto the instrument. Within a dilute and shoot method, 
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there are different steps that must be taken. When a urine sample comes into the 
laboratory, the sample is transferred from the original container to a labeled tube. A 
hydrolysis solution must then be made. The hydrolysis solution contains buffer, internal 
standard and a beta-glucuronidase enzyme. The buffer is used to help minimize the 
change in pH when base or acid is added to the solution.  Buffers are needed for the 
enzyme stability so if the pH changes during the method, it won’t affect the enzyme in a 
negative way. In our method, acetate buffer is used because it has a pH in which the beta-
glucuronidase enzyme will work. If the pH is at a higher or lower pH, the enzyme will be 
unable to work the way it is supposed to. A consistent amount of internal standard is 
added to each sample so that we can have something to compare our unknown samples 
with during data analysis. In the internal standard solution, deuterated compounds are 
used as our standards. Deuterated drugs are drugs in which the hydrogen atoms are 
replaced by a heavier stable isotope deuterium. Deuterated internal standards are used 
because deuterated standards are inexpensive and are easier to incorporate into a method. 
Finally, a beta-glucuronidase enzyme is added, which will help cleave off the glucuronide 
portion from conjugated drugs. Once the hydrolysis solution is made up, an aliquot is 
added to each sample. The samples are then incubated for a certain time and temperature. 
The amount of incubation time is dependent on the temperature preferred by the enzyme 
for maximal activity. If a sample is being heated at 35°C, the samples will need to be 
incubated longer than when a sample is being heated at 65°C. Once the samples are 
heated and incubated, sample diluent is added to dilute the sample down even further. 
After sample diluent is added, the samples have to be centrifuged. Centrifuging the 
samples is critical because we need to get rid of the solid particles in the sample. If solid 
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particles are still present when the samples are injected on the instrument, the solid 
particles will clog up the column which would cause a pressure build up in the system, 
which can lead to failure through leaks. Once they are centrifuged, the supernatant 
sample is transferred into vials to be put on the instrument for analysis.  
 The use of a hydrolysis solution is not always necessary for a laboratory, as not all 
drug classes form glucuronides. Therefore, the use of a hydrolysis solution would be 
beneficial for the classes of drugs that form glucuronides. Also, if a method is looking for 
the glucuronides in urine, then hydrolysis wouldn’t be necessary because the beta-
glucuronidase would be getting rid of what the method is looking for. If the laboratory’s 
method looks for the unconjugated drugs and it is a glucuronide forming class, then 
hydrolysis solution would be necessary.  
Instrumentation 
 When performing a dilute and shoot extraction in urine, most clinical laboratories 
use liquid-chromatography with tandem-mass-spectrometry (LC-MS/MS).  
 In the liquid chromatograph (LC) part of the LC-MS/MS, there are multiple 
different parts which include: pumping system, sample-injection system, columns, and 
detectors. There are 5 requirements according to Skoog that a modern LC should have: (1) 
generation of pressures up to 6000 psi, (2) pulse-free output, (3) flow rates ranging from 
0.1-10 mL/min, (4) flow reproducibilities of 0.5% relative or better, and (5) resistance to 
corrosion by a variety of solvents.24 Unlike with gas chromatography (GC), high pressures 
are not an issue with the LC because liquids are not very compressible and so therefore do 
not pose an explosion risk. The risk that is involved is solvent leakage. Solvent leakage can 
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cause a fire or environmental risk with other solvents. Special care should be taken to 
prevent a solvent leakage. In most commercial chromatographs, the pumping system is a 
reciprocating pump. A reciprocating pump is one in which a small chamber that has the 
solvent is pumped in a back and forth motion of a motor-driver piston. There are two ball-
check valves that open and close alternatively. The valves control the flow of solvent into 
and out of the cylinder. The disadvantage of using this kind of pump is that it produces a 
pulsed flow which appear as a baseline noise on the chromatogram. Dual pump heads and 
elliptical cams are used to help alleviate the pulsed flow in the pumps. The advantages of 
using this pump is the small internal volume, ability to reach high pressures, adaptability 
to gradient elution, large solvent capacities, and the ability to have constant flow rates.24 
 Another part of the LC system is the sample-injection system. The sample-injection 
system is an important part because it is where the sample is being introduced into the 
instrument. The most common way that a sample is introduced onto the column is through 
a sampling loop. In a sampling loop, the sample is injecting into the loop while the loop is 
switched out of the LC flow path. Once the loop is filled with the sample, the loop is 
switched back to the LC flow path where it is then swept onto the head of the LC column.25 
Sampling loops can provide a range of sample sizes from 1 µL to 100 µL and also allowing 
pressures to raise to 7000 psi. In most chromatographs, an auto injector is installed. An 
auto-injector are capable of injecting samples in the LC from vials either on a tray or in a 
carousel. The auto injectors usually already have a sampling loop and a syringe pump that 
can hold a volume of 1 µL to 1 mL.  
 The next part of the LC system is the column. Columns can be made from various 
sources such as stainless-steel tubing, heavy-walled glass tubing, and polymer tubing. 
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There are multiple different packed columns that range according to their size and the 
packing that is used. Most columns range from 5-25 cm long. The inside diameter ranges 
from 3-5 mm.  Particle size inside the column ranges from 3-5 µm. The column used in 
this study had a 2.7 mm diameter range and 2.7 µm particle size. The packing inside of the 
column usually consists of silica. In order to improve the life efficiency of the column, a 
guard column is added. The guard column removes the particulate matter and contaminants 
from the solvents. Once the guard column has become too contaminated, it is then replaced. 
By replacing the guard column, it helps improve the efficiency of the column itself. Guard 
column packing should be similar to the packing of the column being used. Reverse phase 
LC is the most common liquid chromatography method that is used in the LC instrument. 
Reverse phase HPLC uses a polar mobile phase and non-polar stationary phase, and the 
most polar compounds will elute off the column first.  
 The next part of the LC system is the detector. The most common detector that 
would be coupled with a LC is a mass spectrometer. Mass spectrometers aid in the 
identification of the compounds as they come off the column. When the compound comes 
off the column, the first part it encounters in the mass spectrometer is the ion source. The 
ion source is where the compound is formed into gaseous analyte ions. There are two 
different basic types of ion sources: gas phase and desorption. In the instrument that is used 
in this research, the desorption ion source is used. The advantage of using the desorption 
ion source is that volatile and thermally unstable samples can be analyzed. Within the 
desorption ion source type, there are other different types of ion sources. Electrospray 
ionization is what our instrument uses. In electrospray ionization, the ionization takes place 
under atmospheric pressures and temperatures. Part of the sample is pumped through a 
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stainless steel capillary needle at a rate of microliters per minute. The needle is kept at 
several kilovolts. As a result, a charged spray of droplets is emitted and goes through the 
capillary. Within the capillary, evaporation of the solvent and attachment of the charge to 
the analyte occurs. When the droplet becomes smaller, the charge density becomes greater 
until a point called Rayleigh limit which is where the surface tension can no longer support 
the charge. When the limit is hit, a Coulombic explosion occurs and the droplet is broken 
apart into smaller droplets.  
 Once the analyte has been ionized, it now travels to the mass analyzer. In the 
tandem mass spectrometer, there are three quadrupoles, such that these instruments are 
referred to as triple-quadrupole spectrometer. In a quadrupole mass filter, a variable radio-
frequency is also applied to each rod. When the ions are accelerated into the space between 
the rods by a potential difference of 5-10 V, a mass spectrum can be produced. While this 
is occurring, the ac and dc voltages on the rods are increasing simultaneously while 
maintaining their constant ratio. The ions that have the certain m/z charge that is being 
targeted will reach the signal transducer and produce signal. The other non-selected charges 
will strike the rods and become neutral molecules. With a tandem mass spectrometer, there 
are two different mass analyzers present. The first mass analyzer looks for a precursor ion. 
Once the precursor ion is chosen, it is sent to the collision cell, which is also a quadrupole. 
Inside the collision cell, the precursor ion will react with a collision gas and burst into 
fragments and produce product ions. The product ions will then travel to the second mass 
analyzer where it will look for another m/z ratio. Those particular ions will then travel to 





 Research was conducted using six different enzymes to determine which one of 
them had a better hydrolysis efficiency. Of the six different enzymes, three were abalone, 
one was red abalone, one was limpet, and one was recombinant or genetically modified in 
the lab. The six different enzymes that were used were from six different companies: 
Company A, Company B, Company C, Company D, Company E, and Company F. 
 In a study done by Malik-Wolf, researchers used the abalone β-glucuronidase; 
benzodiazepines, opioids, and synthetic cannabinoids were the drugs used to determine the 
hydrolysis efficiency. In this study, solid phase extraction (SPE) was the main technique 
used. Each drug class had different hydrolysis parameters. For the benzodiazepines, 20 µL 
of internal standard was added to 1 mL of specimen. Two mL of 0.1 M sodium acetate 
buffer was also added. The specimen was hydrolyzed with 50 µL of the β-glucuronidase 
followed by an incubation at 70°C for 30 min. After the incubation time, the samples were 
centrifuged for 10 min at 3000 rpm. The specimens were then run on the instrument 
according to the lab’s instrument parameters.  
 For the opioids, 2 mL of the specimen was mixed with 100 µL of internal standard. 
The urine samples were then hydrolyzed with 1 mL of hydrogen chloride (HCl) in an 
autoclave at 15 psi for 45 min and allowed to cool afterwards. The specimens were then 
reacted with 20 µL of 10% hydroxylamine and incubated at 70°C for 15 min. The samples 
were centrifuged at 3000 rpm for 5 min before being put on the SPE column. Finally, the 
synthetic cannabinoids were extracted using a liquid-liquid extraction. Two mL of 
specimen was added with 50 µL of internal standard solution. This was followed by 
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hydrolysis using 1 mL of 0.5 M phosphate buffer and 50 µL of β-glucuronidase. The 
specimens were incubated at 55°C for 30 min. Samples were cooled to room temperature 
where HCl and chlorobutane was added to the samples and they were centrifuged at 3000 
rpm for 5 min. Organic layer was transferred to a clean vial where it was evaporated under 
nitrogen at 55°C. The extracts were reconstituted in 50 µL of mobile phase and then 
transferred to vials to be put on the instrument.  
 The results of this study showed that the abalone β-glucuronidase was able to 
efficiently hydrolyze the benzodiazepines within 20% of the expected concentrations. The 
opioids showed similar results to the other enzyme that was previously done. The abalone 
β-glucuronidase was able to completely hydrolyze the morphine-3-glucuronide. 
Researchers also found that the hydrolysis of the synthetic cannabinoids had shown 
increased results from the method that was currently in use.6  
  Using a recombinant enzyme, results seems to have shown good hydrolysis 
efficiency with buprenorphine and norbuprenophrine. In a study that was presented at the 
Society of Forensic Toxicologists in 2014, the recombinant enzyme had a hydrolysis 
efficiency of 103.8% and 92.6% for buprenorphine and norbuprenorphine respectively. 
The hydrolysis parameters for the drugs were 100 µL of urine, 20 µL of the enzyme, 38 
µL of buffer and 342 µL of water. The study found that complete hydrolysis of 
norbuprenorphine was done at an incubation time of 30 min at 65°C. The maximum 
buprenorphine hydrolysis was found to be without heating or incubation time.8  
In regards to the opioids, one study done showed that they could achieve complete 
hydrolysis of the opiate metabolites. The researchers used 30 µL of fortified urine that had 
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been spiked with the various opioids. Varying amounts of the enzyme was used; anywhere 
from 5-80 µL was used. Depending on how much beta-glucuronidase was used determined 
the incubation time of the samples. The incubation temperature was fixed at 55°C. Both 
the buffer and internal standard were fixed at 90 µL and 30 µL respectively. The samples 
were run using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The 
results showed that for the urine samples that were incubated for only 15 minutes, and 
contained 60 µL of beta-glucuronidase, the enzyme recovered 100% of morphine, 94% of 
oxymorphone, 98% of hydromorphone, and 84% of codeine. Samples incubated at 30 
minutes showed a 90% hydrolysis efficiency for all four glucuronides using only 30 µL of 
enzyme. Researchers concluded that recombinant enzyme was effective in achieving 
complete hydrolysis of opiate metabolites within one hour using 60 µL or less of the 
enzyme.9 
In a study done by Morris, researchers compared the effectiveness of two different 
enzymes: β-glucuronidase from abalone and recombinant enzyme. Drug-free urine was 
fortified with glucuronides of oxazepam, lorazepam, and temazepam at 2,500 ng/mL. An 
internal standard mix was made with the concentration of each internal standard at 1,000 
ng/mL except 7-aminoclonazepam which was at 5,000 ng/mL. The hydrolysis efficiency 
was assessed in triplicate. Two incubation temperatures were used: 55°C and room 
temperature (RT). For the 55°C temperature, the incubation times were 5, 15, 30, and 60 
minutes. For RT, the incubation times were 0, 5, 10, and 15 minutes. Once hydrolysis was 
complete, the samples were centrifuged and injected onto the instrument. The maximum 
hydrolysis of the glucuronides was found at an incubation time of 45 minutes at 55°C and 
at 5 minutes at RT. Researchers stated that there would be a variation in enzyme hydrolysis 
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efficiency due to the influence of the chemical structure and its reactivity with the enzyme. 
Overall, the study showed that recombinant β-glucuronidase was a cleaner extract. The 
study also showed that by using that enzyme, researchers can decrease processing time due 
to no incubation time.10 Eliminating the incubation time step would help speed up the 
process of getting results faster.  
  In one study, enzyme from red abalone was used to find whether or not it could 
hydrolyze cannabinoids. The parameters that were found to have the maximum hydrolysis 
efficiency was using 2000 units of enzyme, 2M sodium phosphate buffer at pH of 6.8, 
incubation time at 16 hours for 37°C. The enzyme was able to have the highest hydrolysis 
efficiency for the 11-Nor-9-Δ9-tetrahydrocannabinol (THCCOOH) compound with 
efficiencies over 99%. The researchers are going to take these results and use them during 
clinical studies that will be investigating monitoring minor cannabinoids to determine if 
researchers can distinguish frequent users from occasional abusers.12  
 Another study used enzyme from red abalone to look at the hydrolysis efficiency 
of morphine and codeine. The urine specimens were spiked with codeine-6-glucuronide, 
morphine-6-glucuornide and morphine-3-glucuronide. Internal standard was added as well 
as a buffer solution at pH 5. The specimens were incubated at 60°C and 68°C for 30 and 
60 minutes. For both codeine and morphine, the greatest hydrolysis efficiency came when 
the incubation time was 60 min at 68°C. The mean recovery was at 95.8%. They also 
compared this enzyme hydrolysis to using acid hydrolysis and found that both hydrolysis 
methods produced similar results. The researchers concluded that enzyme from red abalone 
is capable of achieving complete hydrolysis of both codeine and morphine from their 
glucuronides after only 60 minutes of incubation time.13  
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 Enzyme from limpet helps eliminate the conversion of 6-monoacetylmorphine 
(6MAM) to morphine.14 One study that was done to compare this particular enzyme to 
other types of enzymes such as the E. Coli enzyme and the native limpet enzyme. The study 
also looked at how much 6MAM was converted over to morphine. The parameters for this 
study included enzyme concentration at 65,000 units/mL at pH 5.2 for the limpet enzyme. 
Equal volumes of sample and enzyme stock were added, and incubated at 60°C. For the 
limpet enzyme, the study found that codeine glucuronide conversion was above 95% after 
2 hours of incubation time. They also found that the conversion of 6MAM to morphine 
was below 1% after 2 hours.15 
 There was a study done that used enzyme from abalone that determined the 
hydrolysis efficiency of codeine and morphine. The study used 1 mL of urine sample that 
contained all the internal standards. One mL of 100 mM acetate buffer at pH 5 was added 
along with 50 µL of the enzyme. Samples were vortexed and incubated at 65°C for 1 hour. 
The results showed that for the morphine-3-glucuronide, the hydrolysis efficiency was 
above 90%. However, for morphine-6-glucuronide and codeine glucuronide, the hydrolysis 
efficiency was not all that efficient. Overall, the enzyme from abalone gave the best 









 In this research, the comparison of different beta-glucuronidases is explored. The 
purpose of this research is to determine which of the beta-glucuronidases will produce the 
best hydrolysis efficiency across different drug classes. The hydrolysis efficiency is 
determined by three different factors: incubation time, incubation temperature, and the 
amount of enzyme added to the sample. This section explains the procedures that are 
performed in this research. It outlines materials needed, solution preparation, extraction 
procedure, and instrumentation needed for this research. Since this research did not deal 
with human subjects or protected health information (PHI), no institutional review board 
(IRB) approval was needed.  
Materials  
All samples were analyzed using a Shimadzu HPLC system (Shimadzu 
Corporation, Kyoto, Japan) equipped with a 2 LC-AD solvent pumps, an SIL-20A HT 
autosampler, a CTO-20A column oven, a CBM-20A control module, and an FCV-20AH2 
diverter valve. The HPLC system was attached to a Shimadzu LCMS-8040 liquid 
chromatography tandem-mass spectrometer (LC-MS/MS) system. A Restek® Raptor™
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Biphenyl guard column (2.7 um, 5 x 3.0 mm) and column (2.7 um, 50 x 2.1 mm) were 
used for LC separation (Restek, Bellefonte, PA). The LC-MS/MS is used for clinical 
work in the pain management laboratory located on Oklahoma State University Center 
for Health Sciences (OSU-CHS) campus in Tulsa, OK.  
 Reference standards and glucuronides were purchased through Cerilliant 
(Cerilliant Corporation, Round Rock, TX). Blank drug-free urine was purchased through 
UTAK (UTAK Laboratories, Inc., Valencia, CA). Enzymes were acquired through 
different vendors. The enzymes were mostly in liquid form at 100,000 activity units. 
Company E’s enzyme was purchased in a powder form and had to be reconstituted in 
acetate buffer to get into liquid form.  
The drugs that were of interest to this research are morphine-3-β-D-glucuronide, 
codeine-6-β-D-glucuronide, lorazepam glucuronide, oxazepam glucuronide, (+)-11-Nor-
Δ9-THC-9-carboxylic acid glucuronide, and buprenorphine-3-β-D-glucuronide. The 






 Three different master mix solutions were prepared: a calibrator solution, 
glucuronide solution, and the Internal Standard (IS) solution using deuterated drugs.  
 Two different curves were used during the research. The first curve was made 
using seven different calibration points. Each calibration point was a multiple of the 
lower limit of quantitation (LLOQ). The five calibration points were 0.5c, 1c, 2.5c, 7.5c, 
10c, 15c, and 25c. The 25c is the upper limit of quantitation (ULOQ) for the method and 




is the highest concentration that can be accurately quantitated.  The concentration for 
each point is listed in Table 1 below.  
Table 1. Concentrations for each calibrator point. Concentrations of each analyte at 
the respective calibrator point 
ANALYTE 0.5C 1C 
(LLOQ) 
2.5C 7.5C 10C 15C 25C 
(ULOQ) 
BUPRENORPHINE 10 20 50 150 200 300 500 
CODEINE 10 20 50 150 200 300 500 
LORAZEPAM 10 20 50 150 200 300 500 
MORPHINE 10 20 50 150 200 300 500 
OXAZEPAM 10 20 50 150 200 300 500 
THCA 10 20 50 150 200 300 500 
 
Serial dilutions were done to make working solutions for each calibrator point. The serial 
dilution is located in Table 2 below. 
Table 2. Serial Dilution Table. Serial dilution table for the calibrator points for the first 









25C 87.5       787.5 875 
15C  516      344 860 
10C   510     255 765 
7.5C    405    135 540 
2.5C     190   380 570 
1C      210  315 525 
0.5C       175 175 350 
 
The serial dilutions were done using blank, drug-free urine. Fifty µL of the working 
solutions were aliquoted out into separate labeled Eppendorf tubes and then placed in the 
freezer until needed.  
 The second curve that was used was from the Oklahoma State University Clinical 
Laboratory Services (OSU-CLS). These curves were pre-made for use in urine drug 
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testing laboratory. The OSU-CLS uses a five-point calibration curve. The concentrations 
for each calibrator point are found in Table 3 below.   
Table 3. Concentrations for each calibrator point on FTTL curve. Concentrations of 
each analyte at the respective calibrator point.  
ANALYTE 1C 
(LLOQ) 
2.5C 7.5C 15C 25C 
(ULOQ) 
BUPRENORPHINE 25 62.5 187.5 375 625 
CODEINE 20 50 150 300 500 
LORAZEPAM 20 50 150 300 500 
MORPHINE 20 50 150 300 500 
OXAZEPAM 20 50 150 300 500 
THCA 150 375 1125 2250 3750 
 
Glucuronide Preparation 
 Stock concentrations of each glucuronide were purchased at 100 µg/mL. Samples 
were prepared at 500 ng/mL by diluting 50 µL of each glucuronide’s stock concentration 
in 9700 µL of UTAK urine. Each sample had 50 µL of the glucuronide solution added. 
The glucuronide solution was used as “unknown” in the research so that the hydrolysis 
efficiency could be determined.  
Internal Standard Preparation 
 Internal standard was made that included the respective deuterated standards 






Table 4. Deuterated Internal Standards. List of the drugs and their respective 
deuterated standards. 







THCA  THCA-D3 
 
The internal standard mix was made by adding 50 µL of each deuterated drug to 4800 µL 
of UTAK urine. To each of the samples and the calibration curve, 10 µL of this solution 
was added. The internal standard was added so that a comparison could be made to the 
samples to determine how much of the drug was present in the sample.  
Methods  
 The OSU-CLS clinically validated dilute-and-shoot method was used to prepare 
the calibrators and glucuronide samples for analysis.  The calibration curve was treated 
the same for all 6 enzymes. One difference between the two curves that were used was 
the enzyme. In the first curve, the hydrolysis did not include the enzyme, only 40 µL of 
acetate buffer and 10 µL of internal standard mix was added. When the CLS curve was 
used, the enzyme was included in the hydrolysis solution.  
 The samples were run in triplicate. The hydrolysis preparation was determined by 
the manufacturer’s recommendations. Those recommendations, shown in Table 5, 




Table 5. Manufacturer’s Recommendations. Recommendations from the manufacturer 
on how much enzyme to add, incubation time and incubation temperature.  
Enzyme Beta-Glucuronidase 
(µL) 
Incubation Time Incubation 
Temperature (°C) 
Company A  10 2 hours 55 
Company B 20 30 mins 55 
Company C 5 1 hour 65 
Company D 5 1 hour 60 
Company E 25 2 hours 60 
Company F 10 2 hours 60 
 
There were two constant parameters: amount of internal standard present in each sample, 
10 µL, and amount of urine in each sample, 50 µL. The amount of acetate buffer was 
determined with a final volume of 50 µL. Once the samples were incubated, sample 
diluent was added to dilute the sample prior to analysis on the LC-MS/MS. The sample 
diluent consisted of a 19:1 ratio of water to methanol. The samples were centrifuged for 
10 minutes at 13,000 rpm. Afterwards, 200 µL aliquots of the sample were put into 
amber injection vials and loaded on the autosampler.  
 The LC parameters were based on OSU-CLS’s method. Those parameters are 











Table 6. LC-MS/MS Instrument Parameters. These are the parameters for the LC-
MS/MS. 
LC Parameters for Shimadzu  
Flow Rate 0.35 mL/min 
Column Oven Temperature 30°C 
Injection Volume 10 µL 
MS Parameters for Shimadzu 
Probe Position +1.5 mm 
DL Temperature 250°C 
Heat Block Temperature 400°C 
Nebulizing Gas Flow 3 L/min 
Drying Gas Flow 20.0 L/min 
CID Gas 230 kPa 
Interface Voltage 4.5 kV 
Detector Voltage 1.74 kV 
 
Two mobile phases were used with the method: mobile phase A and mobile phase B. 
Mobile phase A consisted of 2 mM ammonium formate and 0.1% formic acid in water. 
Mobile phase B consisted of 2 mM ammonium formate and 0.1% formic acid in 
methanol. The gradient of the mobile phase was as follows: concentration of mobile 
phase B holds steady at 10% until 1 minute and 40 seconds where the concentration 
increases to 35%. Concentration holds at that point until 2 minutes and 54 seconds when 
the concentration increases to 100%. Concentration holds at 100% for a minute where 
concentration starts to decrease back down to 10%. A 50:25:25 mix of methanol to 
isopropyl alcohol to water was used as the Needle Rinse.   
Data Analysis 
 Data analysis was performed in Browser in the Shimadzu LabSolutions software 
program. From the data, Microsoft Excel was used to calculate a hydrolysis efficiency for 
each beta-glucuronidase enzyme. The hydrolysis efficiency was calculated using the 
concentration outputted from LabSolutions. Once the hydrolysis efficiencies for each 
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beta-glucuronidase enzyme was determined, the results were used in conjunction with 
specific guidelines to determine which beta-glucuronidase enzyme performed the best 









 Hydrolysis efficiencies were calculated using the equation found in Figure 2 





Once the hydrolysis efficiency was calculated for all three samples, an average was 




Figure 2: Hydrolysis Efficiency Equation. Equation used to calculate 
the hydrolysis efficiency of each enzyme and drug 
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Buprenorphine 70.3 76.8 72.4 68.4 69.3 73.6  
65.3 62.3 77.2 75.3 63.6 64.5  
63.9 60.4 70.7 73.2 75.3 62.8 
Codeine 22.3 49.1 49.8 22.1 8.7 59.3  
20.2 52.3 45.9 20.6 8.9 56.7  
19.3 47.7 49.6 21.0 8.8 49.1 
Lorazepam 60.7 58.3 97.3 90.0 97.4 87.5  
56.6 53.6 95.0 98.0 88.3 84.9  
51.9 49.7 104.4 102.1 94.9 84.6 
Morphine 50.6 61.7 60.9 64.2 57.7 62.7  
57.6 56.8 63.5 63.3 53.8 62.7  
50.4 50.2 65.3 65.9 57.9 59.3 
Oxazepam 73.3 75.0 68.0 60.3 74.5 65.6  
69.6 64.4 64.7 69.1 61.2 62.5  
63.0 61.0 70.1 61.3 73.2 58.1 
THCA 28.0 96.5 42.5 75.1 78.9 72.0  
28.3 92.4 51.7 72.1 79.1 78.2  
24.3 85.6 50.8 63.4 79.0 67.8 
 
 
The notable values to mention are from lorazepam, which shows a hydrolysis efficiency 
of higher than 100% for companies C and D. In these particular samples, extra lorazepam 
was not made, the efficiency was higher due to instrument variability. 
Statistical Analysis 
 Analysis of variance (ANOVA) methods were used to analyze each individual 
drug. In total, 6 ANOVAs were performed. If the ANOVA was significant, a multiple 
comparisons post-test was performed to determine the significance between each enzyme 
with the drug classes. The ANOVA results for each individual drug class are found in 
Tables 8-13. A significance level of 0.05 was used. 
Table 7: Hydrolysis Efficiencies. Shown are the hydrolysis efficiencies for companies and the 




Buprenorphine      
Source of 
Variation SS df MS F P-value 
Groups 3568.144478 5 713.6288956 0.935988 0.49193 
Error 9149.204724 12 762.433727   
      
Total 12717.3492 17       
 
 
ANOVA - Codeine      
Source of Variation SS df MS F P-value 
Groups 140585.0803 5 28117.01605 162.5933 1.36E-10 
Error 2075.141628 12 172.928469   
      
Total 142660.2219 17       
 
ANOVA - 
Lorazepam      
Source of 
Variation SS df MS F P-value 
Groups 156492.1188 5 31298.42376 60.61009 4.26E-08 
Error 6196.676039 12 516.3896699   
      
Total 162688.7948 17       
 
ANOVA - 
Morphine      
Source of 
Variation SS df MS F P-value 
Groups 7920.793641 5 1584.158728 5.722944 0.0063 
Error 3321.700489 12 276.8083741   
      
Total 11242.49413 17       
 
 
Table 8: ANOVA for Buprenorphine. Results for the ANOVA for Buprenorphine   
Table 9: ANOVA for Codeine. Results for the ANOVA for Codeine. 
Table 10: ANOVA for Lorazepam. Results for the ANOVA for Lorazepam. 




Oxazepam      
Source of 
Variation SS df MS F P-value 
Groups 3268.403014 5 653.6806028 0.875598 0.525682 
Error 8958.639679 12 746.5533066   
      




ANOVA - THCA      
Source of 
Variation SS df MS F P-value 
Groups 203616.4669 5 40723.29339 77.98325 9.99E-09 
Error 6266.468047 12 522.2056706   
      




Cost efficiency was calculated for each individual enzyme.  Calculations were 
done to determine the cost per sample, personnel cost and the total cost of the enzyme per 
sample. In order to calculate the cost per sample, the amount of samples per bottle had to 
calculated. The amount of samples per bottle was dependent on how much of the enzyme 
was needed for each sample and how big was the bottle of enzyme.  Those numbers are 




Table 12: ANOVA for Oxazepam. Results for the ANOVA for Oxazepam. 
Table 13: ANOVA for THCA. Results for the ANOVA for THCA. 
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Company A 247.50 20,000 10 2,000 $0.12 
Company B 80.00 5,000 20 250 $0.32 
Company C 410.00 10,000 5 5,000 $0.08 
Company D 138.00 10,000 5 2,000 $0.07 
Company E 200.00 10,000 25 400 $0.50 
Company F 80.00 5,000 10 500 $0.16 
 
 
After determining how many sample are in each bottle, the cost of enzyme per sample 
was calculated.  
Personnel cost was another component to consider when thinking of how to help 
laboratories out financially. By taking a base rate of $20/hour for personnel, the cost of 
personnel time could be multiplied by the incubation time to determine how much it 






Table 14: Enzyme Amounts in Bottle. Amount of enzyme in each companies bottle as well as 
how many samples can be completed using just one bottle. The cost per sample was 
determined using cost per bottle and amount of samples in bottle.  
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Enzyme Incubation Time (min) Total Personnel Cost 
Company A 120 $40 
Company B 30 $10 
Company C 60 $20 
Company D 60 $20 
Company E 120 $40 
Company F 120 $40 
 
  
 After determining the personnel cost, the total cost of a sample was calculated. 
The total cost of a sample is the cost per sample plus the personnel cost.  The total cost 
for each enzyme is found in Table 16.  





Company A $0.12 $40 $40.12 
Company B $0.32 $10 $10.32 
Company C $0.08 $20 $20.08 
Company D $0.07 $20 $20.07 
Company E $0.50 $40 $40.50 
Company F $0.16 $40 $40.16 
  
 
Table 16: Total Cost Per Sample. Total cost per sample is the cost per 
sample plus the personnel cost.  
Table 15: Total Personnel Cost. The personnel cost which was calculated using the incubation 
time and hourly rate of $20/hour.  
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 When determining which of the enzymes was the best overall, guidelines were 
set in place to help determine the best overall enzyme prior to any statistical test. It was 
desired to have the top enzyme have specific enzyme performance variables. The 
guidelines used were the enzyme must have a conversion rate of no less than 40% and 
work well across the different drug classes. It must also have a low total cost which 
includes the personnel cost and cost per sample so that it can be cost efficient for a 
laboratory.  
 The first guideline was that the enzyme must have a conversion rate of no less 
than 40%.  Companies A, D, & E were all eliminated because they had at least one drug 
that was below the 40% cutoff. There were no companies that were eliminated due to not 
working well across the drug classes. Companies B, C & F were the last three companies 
left. An ANOVA was completed as well as the multiple comparisons to determine if 
there was any significant difference between these three companies. Once the statistical 
tests were complete, it was found that there was no significant difference between 4 of 
the 6 drugs. Lorazepam and THCA were the only analytes that had any significant 
differences. Between the two drugs, THCA is the hardest one to detect for the clinical 
laboratory method used in this research. By looking at the descriptive statistics, 
lorazepam was significantly better for Company C and THCA was significantly better for 
Company B.  For THCA, Company B had a 91% hydrolysis efficiency compared to 48% 
for Company C. If a laboratory was looking for benzodiazepines specifically then 
Company C would be the obvious choice. However, in this research, an enzyme was 
sought that would work well across multiple drug classes, including THCA, and in this 
case, Company B was the clear best enzyme. The last guideline is that one that helped 
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narrow down the top company. When looking at Table 18, one would assume that 
Company C would be the obvious choice because the cost per sample is lower.  However, 
after looking at Table 16, the choice becomes clear that the top company would be 
Company B because Company C’s enzyme cost almost four times the amount of 
Company B. Also, Company B’s personnel cost is half of what Company C’s personnel 
cost is. Therefore, Company B’s enzyme is the best overall enzyme due to good 







Beta-glucuronidases are a critical component of drug testing as they are a vital 
component of the dilute and shoot process by converting the drug to its free form so that 
it can be easily detected by the LC/MS/MS. The enzymes come in various different forms 
such as patella vulgata, red abalone, abalone and recombinant organisms. Each of the 
different enzymes can work well for certain drug classes, and previous research has 
investigated which enzymes work well for each drug class. When a larger pain panel that 
contains multiple drug classes is used clinically, ideally, it will use an enzyme that will 
work well across all the classes. This increases the amount of the different drug classes 
such, as benzodiazepines, opioids, and cannabinoids available for detection and helps 
avoid false negatives. 
There were different factors in determining which enzyme was the best overall, 
including efficiency and cost. The variables of significance were incubation time, 
incubation temperature and amount of enzyme added. Incubation time and amount of 
enzyme are the two biggest factors to consider. In regard to incubation time, some 
enzymes have to incubate for 2 hours and some for just 30 minutes. If a 2-hour enzyme 
can produce the same results as one that incubates for 30 minutes, then results can be 
produced faster because samples don’t have to be incubated as long. Another factor to 
45 
 
consider is the amount of enzyme that goes into the sample. The variation of the size of 
the bottle and how much enzyme is used per sample can not only help the laboratory with 
the wet lab work but it can also help a laboratory financially. The actual cost per 
specimen analyzed needs to be considered when determining the best overall enzyme. 
The size bottle that a laboratory needs will depend on how many samples a laboratory is 
running per day. If a laboratory is running over 100 samples a day, then they need an 
enzyme that will be cost-efficient for the laboratory in regards to how many samples are 
analyzed. These factors are what led to the decision that Company B was the best overall 
enzyme in this research.  
 In regard to the guideline of working well across the different drugs classes, it 
was found that while some enzymes worked well across the different drugs classes, they 
didn’t necessarily work well within the drug class. Most research that has been done 
looking at the hydrolysis efficiency with beta-glucuronidase enzymes will look at one 
drug in a drug class, such as morphine-3-glucuronide. For example, researchers are 
looking at benzodiazepines and decide to use lorazepam glucuronide and use Company 
C’s enzyme. As shown in this research, Company C’s enzyme has a 98.9% hydrolysis 
efficiency for lorazepam glucuronide. Most researchers would stop there and conclude 
that enzyme C works well for benzodiazepines, but looking at the hydrolysis efficiency of 
67.6% for oxazepam for Company C, it is apparent that the excellent performance on one 
benzodiazepine doesn’t ensure high quality with all benzodiazepines.  
 Another factor to also consider when determining which enzyme is the best is the 
cleanliness of the enzyme. If the enzyme is dirty and has unnecessary particles in it, then 
it may cause interferences and clogging in the LC system. This plays a factor because an 
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enzyme could be 80% efficient but because of how dirty the enzyme is and the 
interferences it will cause; the enzyme might appear to only be 60% efficient. The 
cleanliness of the enzyme is important in determining if the enzyme will have a good 
hydrolysis efficiency.  
 Another consideration that came to light after determining our top enzyme was 
the laboratories’ batch size. It was determined that if a laboratory was to have a batch size 
of 50 samples or more, the cost savings from Company B would start to diminish. If the 
laboratory’s batch size is over 50 samples and they are not concerned with their 
sensitivity to THCA, Company C would be the route to go. However, if a laboratory is 
concerned with their sensitivity to THCA, Company B would be the best choice even 
though the cost savings of Company B would diminish above 50 samples. 
 After this work was completed, each company’s technical notes were reviewed to 
see if this study’s hydrolysis efficiencies were consistent with their expected. For most of 
the companies, the hydrolysis efficiencies observed during this research were lower than 
what the company indicated it would be. One of the companies didn’t have any published 
research on what the hydrolysis efficiency should be for certain classes, so there was no 
point of comparison.  
 There is also a chance that an enzyme that is used could create a false negative 
result depending on which company’s enzyme a laboratory is using. If a particular 
company’s enzyme has a low hydrolysis efficiency for a particular drug, then it will only 
hydrolyze a portion of the glucuronides present which could lead to the drug being below 
the limit of quantitation for the laboratory which would result in a negative result, when 
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the drug is in fact present. If that sample was then sent to another laboratory who uses an 
enzyme that has a great hydrolysis for that same drug, then it could be above their lower 
limit of quantitation which would result in a true positive result. Having an enzyme that 
has a good hydrolysis efficiency will reduce the chances of a false negative.  
In terms of future research, it might be beneficial to attempt to optimize 
conditions for Company B’s enzyme further and investigate making it better. It is 
possible to increase or decrease the incubation temperature, times and amount of enzyme 
to determine if the same results are achieved as the current study. Other glucuronides of 
interest to the clinical laboratory could also be used with the same method in this research 
to see if there are any variations between the drug classes. Lastly, this research used an 
indirect measure of glucuronide hydrolysis efficiency by measuring formation of the 
target drugs. Future research may involve direct measurement of glucuronides by LC-
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